Clinical response to intravenous immunoglobulin inpatients with complex regional pain syndrome (CRPS)

Randomised, double blinded, placebo controlled crossover trial to assess the clinical response to intravenous immunoglobulin inpatients with complex regional pain syndrome (CRPS), and to ascertain pathogenic serum factors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN63918259

Enrollment

Registered

2006-09-29

Start date

2005-11-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex regional pain syndrome (CRPS) Signs and Symptoms Complex regional pain syndrome (CRPS)

Interventions

1. Intravenous immunoglobulin (0.5 g/kg) 2. Placebo Patients were given an infusion of one of the above on two consecutive days, then crossed-over to the other arm for one infusion given on two conse

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 16 patients from Pain Management aged 16 years and older, male and female 2. CRPS of between 6 and 30 months duration 3. Numeric rating scale pain score greater than 4

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women 2. IgA deficiency

Design outcomes

Primary

Measure	Time frame
The average numeric rating scale pain value from day four to day 18 after infusions compared between IVIG and saline	—

Secondary

Measure	Time frame
1. The number of patients who found either treatment more effective 2. The global impression of change values between day four to day 18 after infusions compared between IVIG and saline	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026